For the first time
in 25 years, cancer patients with large B-cell,
CD20positive, non-Hodgkin's lymphoma, have a new drug in the treatment of their cancer. Genentech and Biogen issued
a press release
announcing the U.S. Food and Drug Administration, FDA, approval of Rituxan® in the treatment for large B-cell,
CD20positive, non-Hodgkin's lymphoma. Large B-cell, CD20positive, non-Hodgkin's lymphoma is an aggressive cancer that
can be fatal within six months to two years. Rituxan® is a therapeutic antibody that targets and selectively
depletes CD20-positive B-cells without targeting stem cells or existing plasma cells, and will be administered in
combination with existing chemotherapy treatments. Before this approval, Rituxan® had been used as a single agent
in relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma.Note: The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies, dial 911!
New drug hope for large B-cell non-Hodgkin's lymphoma
For the first time
in 25 years, cancer patients with large B-cell,
CD20positive, non-Hodgkin's lymphoma, have a new drug in the treatment of their cancer. Genentech and Biogen issued
a press release
announcing the U.S. Food and Drug Administration, FDA, approval of Rituxan® in the treatment for large B-cell,
CD20positive, non-Hodgkin's lymphoma. Large B-cell, CD20positive, non-Hodgkin's lymphoma is an aggressive cancer that
can be fatal within six months to two years. Rituxan® is a therapeutic antibody that targets and selectively
depletes CD20-positive B-cells without targeting stem cells or existing plasma cells, and will be administered in
combination with existing chemotherapy treatments. Before this approval, Rituxan® had been used as a single agent
in relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma.
